News

PRISMAP, the European medical radionuclides programme, will end on 31 December 2025. The consortium has just published a press release providing an overview of the user projects funded by the programme.

ITM Isotope Technologies Munich SE (ITM) and the Institut Laue-Langevin (ILL), today announced an extension of their collaboration for medical radioisotope production, originally established in 2009.

An irradiation in ILL’s high flux reactor produced einsteinium-255 that served as on tap supply of fermium-255, enabling high-resolution laser spectroscopy in Mainz.

Curium has just announced an agreement that adds ILL to their global irradiation portfolio to ensure continuous supply of lutetium-177 to benefit more than 100 000 cancer patients over the next five years

The Swiss company NOVARTIS announced at the Choose France Summit the desire to establish a partnership with the ILL, already a partner of other pharmaceutical companies for radioisotope production for cancer treatment and research. This is part of a plan to create a production unit intended to supply the French market with the first radioligand therapy (RLT) drug for the treatment of metastatic prostate cancer, an investment of close to 30 million euros in France.